RxSight (RXST) Equity Average (2020 - 2026)

RxSight (RXST) has 7 years of Equity Average data on file, last reported at $271.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 3.14% year-over-year to $271.5 million; the trailing twelve-month figure through Mar 2026 stood at $271.5 million (down 3.14% YoY), and the FY2025 full-year result was $278.5 million, up 26.11% from the prior year.
• Equity Average for Q1 2026 stood at $271.5 million, down from $275.8 million in the prior quarter.
• Across five years, Equity Average topped out at $280.3 million in Q1 2025 and bottomed at $92.9 million in Q4 2022.
• The 5-year median for Equity Average is $162.1 million (2024), against an average of $197.2 million.
• Peak annual rise in Equity Average reached 226.73% in 2022, while the deepest fall reached 35.72% in 2022.
• A 5-year view of Equity Average shows it stood at $92.9 million in 2022, then jumped by 73.16% to $160.9 million in 2023, then jumped by 73.53% to $279.2 million in 2024, then slipped by 1.23% to $275.8 million in 2025, then slipped by 1.57% to $271.5 million in 2026.
• The last three Equity Average figures came in at $271.5 million (Q1 2026), $275.8 million (Q4 2025), and $277.0 million (Q3 2025), per Business Quant data.

Peer Comparison